AIDS Vaccine Garners Modest Hit
The foremost of its kind HIV vaccine, intended to have a safeguarding effect from the AIDS virus, has shown to have moderate success rate during the course of a latest trial. It is a measured yet important step towards combating AIDS. There are few who perceive that the vaccine would be of any potential effectiveness in the global fight against AIDS. Several experts however state that this vaccine offers a ray of desperately needed optimism to an attempt that has previously been marked by several pricy letdowns.
During the course of a news release, the director of the United States Military HIV Research Program stated that in spite of the trial outcome showing major potential, additional investigation is needed in order to corroborate and further build up on these discoveries.
The trial was a collaborative effort among the United States Army, Thailand, the United States National Institute of Allergy and Infectious Diseases, Sanofi Pasteur and the Global Solutions for Infectious Diseases. It assessed Sanofi’s ALVAC vaccine bolstered with a dosage of GSID’s AIDSVAX.
The trial was carried out in Thailand that commenced in 2003 and had 16,402 HIV-negative enrolments from both sexes, half of whom received the two-part vaccination and the other half received inactive placebo jabs.
During the span of the trial, seventy-four placebo receivers and fifty-one vaccine receivers contracted HIV. The variation wasn’t big, though it turned out to be 31% effective. This meant that it reduced the chances of getting HIV by 31%.
The trial outcome has been quite baffling. It was anticipated that the vaccine receivers who had contracted the disease would have a basic minimum level of safeguard against HIV. However, the study revealed no proof of such safety. The levels of HIV in vaccine receivers were noted to be at levels analogous to those placebo receivers that caught the virus.
Conceivably the major letdown was that the study fails to achieve its targeted 50% effectiveness rate in lowering HIV risk. The study had been contentious since its commencement and was the widest scale HIV vaccine trial ever carried out. Some AIDS campaigners have identified the trial as wastage of crucial reserves.
AIDSVAX, the foremost HIV vaccine to have undergone testing, has already botched in HIV prevention during the series of trials. ALVAC, a live canarypox viral form that bore HIV genes, didn’t appear to trigger effectual immunity reactions in healthy individuals. Analogously permutated vaccine strategies displayed hardly any proof of educing strong immunity reactions.
Furthermore, a comparable study carried out on the ALVAC and AIDSVAX vaccines has been annulled in the United States. And sceptics mention that the pattern of study design would make it trickier to decipher what section of the vaccine schedule was being effectual or not.
With the study having reached its final leg, scientists would delve deeper into the finer nuances of it and in the process attempt to decode its workability factor and try building on that achievement.
The vaccine product manager for the United Stated Army, Colonel Jerome Kim during the course of a news release stated that the know-how derived from this study would be beneficial in propelling future study plans and testing as scientists continually endeavour to probe for a safe, internationally effectual HIV vaccine.
Popularity: 62% [?]
